Back in April 2014, it was announced that BlackBerry had made a strategic investment in end-to-end medical solutions provider NantHealth. That relationship grew further during CES 2015 with the announcement that BlackBerry would be providing the software platform for NantHealth's HBox. Now, the Culver City, California-based company has filed for an Initial Public Offering (IPO) worth possibly as much as $92 million.
Joining BlackBerry as investors in NantHealth are Allscripts, Verizon, Kuwait, and Celgene. The S-1 filing with the Securities and Exchange Commission on May 6, 2016, makes for an interesting read as it not only breaks down the revenues for NantHealth, which despite a $72 million net loss in 2015, are actually up 72-percent to $58.3 million from 2014's $33.9 million, but also highlights their plans to expand aggressively in Canada, the United Kingdom and Southeast Asia, along with laying out the plans for their knowledge, provider and payer platform known as CLINICS, short for Comprehensive Learning Integrated NantHealth Intelligent Clinical System.
At this point, it's hard to say what it all means for BlackBerry's portion of the investment but again, looking through the S-1 filing, it would appear as though BlackBerry and QNX are very much a part of NantHealth's operations, especially in the OS and hardware sections of the business. The filing even notes, the two companies are collaborating on the development of HIPAA-certified integrated clinical systems that transform the delivery of medical care. NantHealth intends to list its common stock on the NASDAQ Global Market under the ticker symbol "NH."
NantHealth Files Registration Statement for Proposed Initial Public Offering
CULVER CITY, Calif.--(BUSINESS WIRE)--NantHealth, LLC, a leading next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of common stock to be sold in the offering will be offered by NantHealth. The number of shares to be offered and the price range for the proposed offering have not yet been determined. NantHealth intends to list its common stock on the NASDAQ Global Market under the ticker symbol "NH."
Jefferies LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering, and First Analysis Securities Corporation and FBR Capital Markets & Co. are acting as co-managers.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus may be obtained from: Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340 or by email at [email protected]; or Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (631) 274-2806 or by fax at (631) 254-7140.
NantHealth, a member of the NantWorks ecosystem of companies, is a leading next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. Our unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, we have developed an adaptive learning system, CLINICS, which includes our unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time. As a pioneer in the era of big data and augmented intelligence, we believe we are uniquely positioned to benefit from multiple significant market opportunities as healthcare providers and payors transition from fee-for-service to value-based reimbursement models and accelerate their pursuit of evidence-based clinical practice.
Our mission is to empower providers to seamlessly act on the best evidence-based information available to better fulfill their roles as caregivers rather than as financial managers, to provide payors with the necessary tools to better fulfill their roles as stewards of an increasingly complex and rapidly evolving healthcare system, to facilitate biopharmaceutical companies to accelerate development of drugs for critical illnesses based upon the unique biology and specific health conditions of patients, and to empower patients with the knowledge to enable active participation in the management of their own health, or self-care.